Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Avidity Biosciences ( (RNA) ) has shared an announcement.
On August 1, 2025, Avidity Biosciences entered into a Manufacturing Services Agreement with Lonza to produce drug substances and products for future commercial use, committing to purchase approximately $620 million in products from 2026 to 2028. This agreement supports Avidity’s preparation for potential product launches, as the company progresses with its RNA therapeutic programs, including three potential BLA submissions within a year. Avidity’s strong financial position, with cash reserves expected to fund operations until mid-2027, underpins its readiness for global commercialization starting in 2026.
The most recent analyst rating on (RNA) stock is a Buy with a $56.00 price target. To see the full list of analyst forecasts on Avidity Biosciences stock, see the RNA Stock Forecast page.
Spark’s Take on RNA Stock
According to Spark, TipRanks’ AI Analyst, RNA is a Neutral.
Avidity Biosciences’ overall score is driven by strong technical momentum and positive corporate events, which are offset by financial performance challenges and valuation concerns. The company’s strategic advancements in drug development are promising, but profitability and cash flow remain critical areas for improvement.
To see Spark’s full report on RNA stock, click here.
More about Avidity Biosciences
Avidity Biosciences, Inc. is a biopharmaceutical company focused on delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™). These therapeutics aim to improve lives by combining the specificity of monoclonal antibodies with the precision of oligonucleotide therapies, targeting diseases previously unreachable with existing RNA therapies. Avidity is leading clinical development programs for rare muscle diseases such as myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy (DMD), and facioscapulohumeral muscular dystrophy (FSHD), and is also advancing candidates for rare genetic cardiomyopathies.
Average Trading Volume: 2,142,428
Technical Sentiment Signal: Strong Buy
Current Market Cap: $4.61B
Learn more about RNA stock on TipRanks’ Stock Analysis page.